Farkad Ezzet
Schering-Plough
5 Papers
43 Citations
Farkad Ezzet is an academic researcher from Schering-Plough. The author has contributed to research in topics: Population & Posaconazole. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Oral Bioavailability of Posaconazole in Fasted Healthy Subjects: Comparison Between Three Regimens and Basis for Clinical Dosage Recommendations
TL;DR: It is suggested that divided daily dose administration (every 12 or 6 hours) significantly increases posaconazole exposure under fasted conditions and significantly increases the bioavailability fraction among regimens.
206
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
TL;DR: A population pharmacokinetic (PPK) model for ezetimibe that incorporates enterohepatic recirculation was developed, confirming the appropriateness of the former measures as a surrogate of drug exposure for a possible correlation with pharmacodynamics and assessing the correlation between observed maximum or minimum concentration and model-based area under the curve.
125
The plasma concentration and LDL-C relationship in patients receiving ezetimibe.
Farkad Ezzet,Deborah J. Wexler,Paul Statkevich,Teddy Kosoglou,James E. Patrick,Leslie Lipka,L. Mellars,Enrico P. Veltri,Vijay Batra +8 more
TL;DR: It is confirmed that a daily 10 mg dose of ezetimibe is an optimal therapeutic dose in the treatment of hypercholesterolemia, and taken as a surrogate for concentrations at the enterocyte.
61
Population pharmacokinetic analysis of pegylated interferon alfa‐2b and interferon alfa‐2b in patients with chronic hepatitis C
TL;DR: This study quantified pharmacokinetic changes in pegylated and nonpegylated interferon alfa‐2b during 48 weeks of treatment and the influences of covariates on the basis of sparsely sampled serum concentrations and activity values.
45
Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis
David R. Andes,K. Marchillo,R. Conklin,Gopal Krishna,Farkad Ezzet,Anthony Cacciapuoti,David Loebenberg +6 more
TL;DR: Investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy and was predictive of treatment success in both experimental models and clinical trials.